Impact of immunosuppression on mortality in critically ill COVID-19 patients

Br J Haematol. 2020 Nov;191(3):394-395. doi: 10.1111/bjh.17108. Epub 2020 Oct 26.

Authors

Adrien Mirouse^{1

2}, Michaël Darmon^{1

2}, Lara Zafrani^{1

2}, Etienne Lengliné³, Elie Azoulay^{1

2}

Affiliations

¹ Service de médecine intensive et réanimation, hôpital Saint-Louis, APHP, Paris, France.
² Université de Paris, Paris, France.
³ Service d'hématologie, hôpital Saint-Louis, APHP, Paris, France.

PMID: 33103761
DOI: 10.1111/bjh.17108

No abstract available

Publication types

Comment

MeSH terms

Aged
Betacoronavirus*
COVID-19
Confounding Factors, Epidemiologic
Coronavirus Infections / complications
Coronavirus Infections / immunology
Coronavirus Infections / mortality*
Critical Care
Critical Illness / mortality*
Female
Hematologic Neoplasms / complications
Hematologic Neoplasms / drug therapy
Hematologic Neoplasms / immunology
Humans
Immunocompromised Host*
Immunosuppressive Agents / adverse effects*
Male
Middle Aged
Neoplasms / complications*
Neoplasms / drug therapy
Neoplasms / immunology
Organ Dysfunction Scores
Organ Transplantation
Pandemics
Pneumonia, Viral / complications
Pneumonia, Viral / immunology
Pneumonia, Viral / mortality*
Postoperative Complications / immunology
Prospective Studies
SARS-CoV-2

Substances

Immunosuppressive Agents